RMi Pre-opening: New highs, say BYE?

January 7, 2026 8:12am

Dramatic upsides usually come at a price

Pre-open Signals: 2 Sell into Strength and 4 Negative; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

Tuesday’s (1/6) RMi Closing Bell: Elasticity … https://www.regmedinvestors.com/articles/14256

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! …

https://www.regmedinvestors.com/articles/14249   

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, financings and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Wednesday: The pre-open Dow futures are UP +0.06% or (+30 points), the S&P futures are DOWN -0.04% or (-3 points) and the Nasdaq futures are DOWN -0.18% or (-45 points)

• U.S. stock futures were mixed and barely moving, Wednesday 1/7,
• European markets were trending mixed,
• Asia Pacific markets were regionally mixed

Economic Data:  ADP Employment, 10 am - JOLTS Job Openings, 10 am - ISM Services and again 10 am - Factory Orders

• On Friday, the December jobs report is expected to show a slowdown in hiring in the final month of 2025, with economists expecting nonfarm payrolls to grow by 55,000, down from November's job gains of 64,000. The unemployment rate, which hit a four-year high of 4.6% in November, is expected to fall by 0.1%.

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Tuesday: The Dow closed UP +484.90 points or +0.99%, the S&P closed UP +42.67 points or +0.62% while the Nasdaq closed UP +151.351 points or +0.65%
• Monday: The Dow closed UP +594.79 points or +1.23%, the S&P closed UP +43.58 points or +0.64% while the Nasdaq closed UP +160.193 points or +0.69%
• Friday: The Dow closed UP +319.10 points or +0.66%, the S&P closed UP +12.97 points or +0.19% while the Nasdaq closed DOWN -6.362 points or -0.03%

• Last week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.
• The previous week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
• December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

Q1/26 – Q1 – 1 holiday, 1 negative and 2 positive closes  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Arrowhead Pharmaceuticals (ARWR) closed up +$6.93 after Monday’s -$3.91 with a negative -$1.91 or -2.70% pre-open

Sarepta Therapeutics (SRPT) closed up +$1.28 with a negative -$0.09 or +0.40% pre-open

Ultragenyx Pharmaceuticals (RARE) closed down -$0.57 after Monday’s -$0.49 after Friday’s +$0.60 with a negative -$0.42 or -1.86% pre-open

Sell into Strength:

Capricor Therapeutics (CAPR) closed up +$1.32 after Monday’s -$3.50, Friday’s -$0.55 (-1.91% to $28.31) pre-open NO indication …as CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!

•             I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.

•             Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!

•             CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.

•             It has begun; timing will be everything!

•             The higher CAPR rises, the steeper the fall!

CRISPR Therapeutics (CRSP) closed up +$3.03 after Monday’s +$1.38 after Friday’s +$1.33 with a nrgative -$0.81or -1.40% pre-open

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

• Sticking to the title's theme: "New highs, say BYE? Dramatic upsides usually come at a price ...

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

• after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

January – 2nd week’s session

• 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
• 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

First week:

• 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
• 1/1 -Thursday was a holiday, New Years Day

Last week of December, Q4 and FY25

• Wednesday closed negative with 18 positive, 22 negative and 5 flats
• Tuesday closed negative with 7 positive, 31 negative and 2 flats
• Monday closed negative with 12 positive, 24 negative and 4 flats

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in past session:   

• Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)

• Monday: IQVIA Holdings (IQV), BioLife Solutions (BLFS), and Vericel (VCEL)

The worst three (3) in past session:

• Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)
• Monday: Capricor Therapeutics (CAPR), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.